Second bone marrow transplantation for leukemia in untreated relapse

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Relapsed acute leukemia and juvenile chronic myelomonocytic leukemia (JCMML) pose significant therapeutic challenges.
• Second bone marrow transplantation (BMT2) is an option for patients relapsing after initial BMT.
• Outcomes and complications of BMT2 require further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of second bone marrow transplantation (BMT2) in patients with relapsed acute leukemia and JCMML.
• To analyze the conditioning regimens and GVHD prophylaxis used in BMT2.
• To assess long-term outcomes, including remission status and survival.

Main Methods:

• Retrospective analysis of eight patients undergoing BMT2 for relapsed acute leukemia (4 ANLL, 3 ALL) and JCMML.
• Review of conditioning regimens for both first (BMT1) and second (BMT2) transplants.
• Assessment of graft-versus-host disease (GVHD) incidence, severity, and management.
• Evaluation of engraftment, relapse rates, and survival post-BMT2.

Main Results:

• Six of eight patients engrafted after BMT2.
• Two patients died early without residual leukemia.
• One patient relapsed 6 months post-BMT2.
• Five patients developed severe acute GVHD (grades III-IV), leading to fatal outcomes in three.
• Two patients achieved continuous complete remission (CR) at 12 and 36 months post-BMT2.

Conclusions:

• Second bone marrow transplantation (BMT2) can lead to durable remissions in a subset of patients with relapsed leukemia.
• Severe acute graft-versus-host disease (GVHD) remains a major challenge and cause of mortality after BMT2.
• Further optimization of conditioning and GVHD prophylaxis strategies is crucial for improving BMT2 outcomes.